What is cold agglutinin disease?

What is Cold Agglutinin Disease?

Cold agglutinin disease (CAD) is a rare autoimmune hemolytic anemia caused by monoclonal IgM autoantibodies (typically IgM-κ) that bind to red blood cell antigens at low temperatures, triggering complement-mediated hemolysis through the classical pathway. 1, 2

Pathophysiology

CAD represents a dual disorder: it is both a clonal B-cell lymphoproliferative disorder of the bone marrow and a complement-mediated hemolytic process. The disease mechanism involves:

• Monoclonal IgM antibodies (usually IgM-κ class) that interact with specific red cell antigens below physiologic temperatures
• Complement activation via the classical pathway (C1-initiated), leading predominantly to C3b-mediated extravascular hemolysis in the liver
• Cold agglutinin titers typically greater than 1:1,000 in most cases 3
• The cold agglutinins are frequently encoded by the IGHV4-34 gene segment 4

Intravascular hemolysis occurs primarily during acute exacerbations, while chronic extravascular hemolysis predominates in stable disease 2.

Clinical Presentation

Patients with CAD experience three major clinical manifestations:

1. Chronic hemolytic anemia with associated fatigue and weakness
2. Cold-induced circulatory symptoms including Raynaud phenomenon, acrocyanosis, and cold urticaria affecting fingers, ears, and nose 1, 5
3. Elevated thromboembolic risk requiring consideration of prophylaxis 2, 6

The disease occurs in fewer than 10% of patients with Waldenström macroglobulinemia but can also present as a primary disorder 3.

Diagnostic Criteria

The diagnosis requires four essential elements 7, 2, 6:

1. Evidence of chronic hemolysis (elevated LDH, indirect bilirubin, reticulocytosis, low haptoglobin)
2. Monospecific direct antiglobulin test (DAT) positive for C3d but negative for IgG - this is pathognomonic
3. Cold agglutinin titer ≥ 1:64 at 4°C (though titers >1:1,000 are typical in CAD)
4. Bone marrow evaluation to document clonal lymphoproliferative disorder and exclude malignant lymphoma or other causes

Critical Diagnostic Pitfall

All samples must be handled at 37°C to prevent falsely low IgM measurements and ensure accurate testing 3, 7. The thermal amplitude (the highest temperature at which cold agglutinins remain active) predicts clinical severity better than titer alone 2.

Distinction from Cold Agglutinin Syndrome (CAS)

CAD must be distinguished from secondary cold agglutinin syndrome (CAS), which occurs secondary to infections (especially Mycoplasma, EBV), malignant lymphomas, or other disorders. CAS is managed by treating the underlying cause, not with CAD-specific therapies 2, 4.

Associated Conditions

CAD frequently occurs in the context of:

• IgM MGUS (monoclonal gammopathy of undetermined significance) - mainly IgM-κ 1
• Waldenström macroglobulinemia - in fewer than 10% of WM patients 3
• Type I cryoglobulinemia - coexistent in some patients, contributing to cold-induced symptoms 3, 4

The 2022 WHO classification now recognizes CAD-associated lymphoproliferative diseases as distinct entities 2.

Clinical Significance

Beyond anemia, CAD causes:

• Profound, disabling fatigue that responds to effective therapy
• Cold-induced circulatory compromise requiring lifestyle modifications
• Risk of acute hemolytic crises with cold exposure
• Thromboembolic complications requiring prophylactic consideration 2, 6

The disease burden is substantial, with significant impact on quality of life even when hemoglobin levels are only moderately reduced 6, 4.